Many preclinical studies showed high efficacy of CCL2/CCR2 antagonists, e.g., in the mouse model of lung adenocarcinoma, targeting CCR2 with a small molecule inhibitor not only reduced recruitment of M2-type macrophages but also induced tumor infiltration of activated CD8+ T cells [116]. Here, CCL2 is linked to neoplasm.